Accelerating High-Titer Expression for Complex Next-Gen Biologics
Webinar Date/Time: Thu, Oct 31, 2024 11:00 AM EDT
Learn how to accelerate the high-titer production of next-generation multispecific antibodies and complex protein biologics.
Register Free: https://www.biopharminternational.com/bp_w/next-generation-biologics
Event Overview:
Join us to learn how the GPEx® Lightning platform accelerates the high-titer production of next-generation multispecific antibodies and complex protein biologics with unmatched speed, flexibility and scalability. Participants will gain insights into how GPEx® Lightning improves production efficiency, reduces the development and production timeline, making it ideal for commercial manufacturing. Additionally, we will cover its tunable expression capabilities, which ensure balanced multi-gene or multi-chain expression, particularly for complex and hard-to-express proteins, while maintaining consistent quality. Explore how GPEx® Lightning’s flexibility supports innovation in next-generation biologics development and learn how your team can leverage its unique advantages for commercial success.
Key Learning Objectives:
- Understand how GPEx® Lightning provides a unique advantage with enhanced production efficiency.
- Discover how tunable expression is designed to deliver balanced expression of multi-chain or multi-gene cell lines.
- Explore the flexibility and adaptability that GPEx® Lightning can offer for your next-generation biologics development needs.
Who Should Attend:
- Chief scientific officers
- Process development scientists
- CMC engineers
- Bioprocessing engineers
- Upstream development scientists
- CEOs, VPs & Directors of biologic development
- VPs & Directors of bioprocessing
- VPs & Directors of process development
- VPs & Directors of biomanufacturing
- VPs & Directors of bioproduction
Speaker:
Laura Daley, PhD
Senior Director, Molecular & Cellular Biology
Catalent Biologics
Dr Laura Daley is a senior director at Catalent Pharma Solutions, where she supports cell line development, R&D, and cell and molecular biology activities. Laura received her PhD in pharmacology and physiology from the Saint Louis University School of Medicine before joining the Department of Pediatrics at Stanford University School of Medicine as a postdoctoral fellow. Her background includes the fields of stem cell biology, gene regulation and genetic engineering. She has over 16 years of industry experience where she has played a fundamental role in immune cell gene editing, developing applications to advance the immuno-oncology field. At Catalent, she continues to leverage her expertise in science, strategy and innovation to advance products and technology contributing to the manufacturing of biologics.
Register Free: https://www.biopharminternational.com/bp_w/next-generation-biologics
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
